RecruitingNot ApplicableNCT06232226

Attention Deficit Hyperactivity Disorder

Addictions and Attention Deficit Disorder With or Without Hyperactivity


Sponsor

Nantes University Hospital

Enrollment

60 participants

Start Date

Apr 11, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

The ADA cohort aims for the systematic and standardized collection of sociodemographic, clinical and neuropsychological data, during 2 visits (inclusion and 12 months), from patients suffering from the co-occurrence of ADHD (Attention Deficit Hyperactivity Disorder) and addiction(s), in addition to the treatment as usual adapted to each situation.


Eligibility

Min Age: 15 YearsMax Age: 99 Years

Inclusion Criteria6

  • Patients aged over 15 years and 3 months
  • For whom a diagnosis of ADHD has been confirmed less than 6 weeks ago
  • For whom the diagnosis of one or more addictive disorder(s) (substance use disorder or behavioral addiction) has been confirmed
  • Meeting the indication for treatment with MPH according to European recommendations (Kooij et al., 2019)
  • For patients who can actually benefit from MPH: who have not yet started taking MPH
  • Social security affiliates

Exclusion Criteria4

  • Presenting disorders of higher cognitive functions (at the discretion of the referring clinician or the investigator making the inclusion), making data collection impossible
  • Presenting difficulties in reading or writing the French language making data collection impossible
  • Unable to commit to being available for the 2 visits planned as part of the cohort
  • Under guardianship or legal protection

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERPatients suffering from the co-occurrence of ADHD and addiction(s)

All eligible patients over 15 years and 3 months (age limit between child psychiatry and adult psychiatry), presenting both a diagnosis of ADHD and a diagnosis of at least one addictive disorder (SUD, AUD (Alcohol Use Disorder) and/ or behavioral addiction), starting care in one of the three participating centers, and meeting the indication for treatment with MPH according to European recommendations (J. J. S. Kooij et al., 2019)


Locations(3)

Nantes University Hospital

Nantes, Loire-Atlantique, France

CHRU de Brest

Brest, France

CHRU de Tours

Tours, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06232226


Related Trials